

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

MUTZ-5

RRID:CVCL_1873

Type: Cell Line

Proper Citation

DSMZ Cat# ACC-490, RRID:CVCL_1873

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1873

Proper Citation: DSMZ Cat# ACC-490, RRID:CVCL_1873

Description: Cell line MUTZ-5 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: B acute lymphoblastic leukemia

Defining Citation: [PMID:11516110](#), [PMID:15843827](#), [PMID:22460905](#), [PMID:26589293](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#)

Comments: Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MUTZ-5

Synonyms: Mutz-5, MUTZ5, Menschliche Und Tierische Zellkulture-5

Cross References: ArrayExpress:E-MTAB-2770, BioSample:SAMN03473564, BioSample:SAMN10988511, cancercellines:CVCL_1873, Cell_Model_Passport:SIDM01689, Cosmic:1130257, Cosmic:1278371, Cosmic:1519165, Cosmic:1524809, DepMap:ACH-000492, DSMZ:ACC-490, DSMZCellDive:ACC-490, GEO:GSM887343, GEO:GSM888419, IARC_TP53:30125, LiGeA:CCLE_431, PharmacDB:MUTZ5_971_2019, Progenetix:CVCL_1873, Wikidata:Q54907101

ID: CVCL_1873

Vendor: DSMZ

Catalog Number: ACC-490

Record Creation Time: 20220427T220828+0000

Record Last Update: 20260815T234700+0000

Ratings and Alerts

No rating or validation information has been found for MUTZ-5.

No alerts have been found for MUTZ-5.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. Cell, 188(2), 331.

Oikonomou A, et al. (2024) Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening. Heliyon, 10(13), e34033.

Arwood ML, et al. (2023) New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation. Cell chemical biology, 30(6), 618.